View Older Stories View More Recent Stories
-
BREAKING: Hims & Hers Health, Inc. (HIMS) has been Sued for Securities Fraud, Investors are Notified to Contact BFA Law before Court Deadline
-
HIMS ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Hims & Hers Health, Inc. Investors
-
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
-
LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
-
Hims & Hers (HIMS) hires former Robinhood (HOOD) VP of Product Dheeja Kaur as CPO
-
HIMS SECURITIES ALERT: Hims & Hers Health, Inc. Investors are Notified to Contact BFA Law about its Pending Securities Fraud Investigation
-
HIMS INVESTIGATION ALERT: BFA Law Notifies Hims & Hers Health, Inc. Investors with Losses to Contact the Firm about its Securities Fraud Investigation
-
Compounding Crisis: Johnson Fistel's Probe into Hims & Hers' Semaglutide Scandal
-
Hims & Hers Health, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow HIMS Investors to Recover Losses
-
Deutsche Bank Reiterates Hold Rating on Hims and Hers (HIMS)
-
Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Hims & Hers (HIMS) CEO responds to Novo Nordisk (NVO) news
-
HIMS Alert: Kehoe Law Firm, P.C. Investigating Potential Securities Fraud Claims on Behalf of Investors of Hims & Hers Health, Inc.
-
Needham Downgrades Hims and Hers (HIMS) to Hold, Removes from Conviction List
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1 put with a focus on June 27 weekly options as share price down 28%
-
Truist on Hims and Hers (HIMS): 'we do not believe branded Wegovy was driving any meaningful subscriber or revenue for HIMS'
-
Leerink on Hims and Hers (HIMS): 'stock volatility tied to weight loss has limited the ability to find a fundamentally palatable valuation'
-
Morgan Stanley on Hims and Hers (HIMS): 'The abrupt change could renew concerns over litigation'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28, 'Litigation risk now front and center'
-
Novo Nordisk (NVO) terminates collaboration with Hims & Hers Health (HIMS) due to concerns about their illegal mass compounding and deceptive marketing
-
Hims & Hers stock falls after Novo Nordisk ends weight loss drug pact
-
Hims & Hers Health, Inc. (HIMS) Falls 18% After Pact with Novo Nordisk Ends
-
BofA on Hims and Hers (HIMS), PT $28: 'core revenue growth y/y has slowed sharply'
-
Morgan Stanley on Hims and Hers (HIMS): 'Sharp deceleration in app downloads and web traffic in the month of May'
-
Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
-
Hims and Hers (HIMS) PT Raised to $65 at Needham
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
TD Cowen on Hims and Hers (HIMS): 'acquisition of ZAVA reflects its commitment to expand into international markets'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.1 calls to 1 put with a focus on June 60, 65 and 70 calls as share price up 4.7%
-
Hims & Hers Health, Inc. (HIMS) Rapidly Selling $6 to a 60 Handle, Remains +675bps on Day
-
Truist on Hims and Hers (HIMS): 'likely has the opportunity to up-sell', 'we believe HIMS is likely to still have financial capacity to announce additional deals'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30
-
Leerink Partners on Hims and Hers (HIMS): 'we do see some execution and integration risk associated with the deal'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), 'Core growth in US slowing notably'
-
Hims & Hers Health, Inc. (HIMS) to Acquire ZAVA
-
Hims & Hers Health, Inc. (HIMS) To Acquire European Telehealth Platform Zava - CNBC
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put with a focus on June 6 weekly calls as share price up 2.3%
-
Hims and Hers (HIMS) to cut over 4% of staff amid strategy shift - Bloomberg
-
Hims & Hers Health, Inc. (HIMS) Introduces 6-Month Wegovy New Customer Offer
-
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
-
Hims & Hers Health: Analysts remain bearish
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
BofA Securities Negative on Hims and Hers (HIMS): 'Observed total sales and GLP-1 sales decline in April'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'
-
Truist: 'we share some interesting takeaways from the ruling that could provide a read through on the Wegovy/Ozempic case'
-
Hims and Hers (HIMS) PT Raised to $45 at Truist, 'unless the company's Q2 revenues exceed its current guidance, the ramp reflected in HIMS' 2H outlook might be a stretch'
-
Hims & Hers Health, Inc. (HIMS) Announces Proposed Convertible Senior Notes Offering
-
Hims & Hers Health, Inc. (HIMS) Appoints Mo Elshenawy as CTO
